Impax Provides an Update on FDA Inspection of Hayward Facility

Impax Laboratories (NASDAQ: IPXL ) today announced that the U.S. Food and Drug Administration (FDA) completed its re-inspection of the Company's Hayward manufacturing facility in connection with the previously disclosed Form 483 issued in March 2012. In addition to the re-inspection, the FDA conducted a Pre-Approval Inspection (PAI) for